NCT05059522 2026-04-14
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
Phase 3 Active not recruiting
Clinical Trials
12 trialsNCT03815643 2026-03-31
Avelumab Program Rollover Study
EMD Serono
Phase 3 Active not recruiting
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT02576574 2025-01-31
Avelumab in First-line NSCLC (JAVELIN Lung 100)
EMD Serono
Phase 3 Completed
NCT02603432 2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3 Completed
NCT02580058 2023-07-10
JAVELIN Ovarian 200
Pfizer
Phase 3 Completed
NCT02625610 2022-06-09
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
EMD Serono
Phase 3 Completed
NCT02952586 2021-09-22
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
Pfizer
Phase 3 Terminated
NCT02951156 2020-12-17
Javelin DLBCL
Pfizer
Phase 3 Terminated
NCT02625623 2020-11-24
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
EMD Serono
Phase 3 Completed
NCT02395172 2020-08-03
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
EMD Serono
Phase 3 Completed
NCT02718417 2020-07-14
JAVELIN OVARIAN 100
Pfizer
Phase 3 Terminated